Article Sidebar

PDF
Issue: Vol. 567 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v567i1.19289
Date Published: 05/11/2026
Views 41
Downloads 22
How to Cite
Hoàng, T. T. N., Phạm, Q. T., Đào, H. G., & Nguyễn, Q. T. (2026). IRREGULAR ANTIBODY IDENTIFICATION IN DARATUMUMAB-TREATED PATIENTS WITH MULTIPLE MYELOMA AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION. Vietnam Medical Journal, 567(1). https://doi.org/10.51298/vmj.v567i1.19289

IRREGULAR ANTIBODY IDENTIFICATION IN DARATUMUMAB-TREATED PATIENTS WITH MULTIPLE MYELOMA AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION

Thị Thanh Nga Hoàng1, , Quang Thịnh Phạm1,2, Hương Giang Đào1, Quang Tùng Nguyễn1,2
1 Viện Huyết học – Truyền máu Trung ương
2 Trường Đại học Y Hà Nội

Main Article Content

Abstract

Objective: To describe the results of irregular antibody identification in patients with multiple myeloma receiving Daratumumab after mitigation of anti-CD38 interference at the National Institute of Hematology and Blood Transfusion.


Study design: A cross-sectional descriptive study.


Study setting: The study was conducted at the National Institute of Hematology and Blood Transfusion, Vietnam, from January 2023 to December 2026.


Subjects: 69 patients with multiple myeloma receiving Daratumumab who were indicated for irregular antibody screening.


Results: Before mitigation of anti-CD38 interference, 100% of patients treated with Daratumumab had positive irregular antibody screening results. After mitigation of anti-CD38 interference, alloantibodies were detected in 15.9% of patients. Two alloantibodies, anti-Mia (63.6%) and anti-E (36.4%), were identified. The median anti-CD38 antibody titer was markedly higher than the median alloantibody titer (1024 vs. 4, respectively).


Conclusion: Mitigation of anti-CD38 interference facilitates the identification of irregular antibodies in patients with multiple myeloma treated with Daratumumab.

Keywords

Multiple myeloma, Daratumumab, irregular antibodies

Article Details

References

1. Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies. Front Immunol. 2018;9:2616.
2. Engström C, Scherrer E, Falconer J, Londero D, Penatejera C, Legoff I, et al. Multicenter evaluation of soluble CD38: Neutralizing anti-CD38 pan-reactivity to enable alloantibody detection: CD38 pretreatment: A key to alloantibody detection. Blood Transfus. 2025.
3. Brecher ME. Technical Manual. 15th ed. Bethesda (MD): American Association of Blood Banks; 2005.
4. Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):1091–1110.
5. Phou S, Costello C, Kopko PM, Allen ES. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens. Transfusion. 2021;61(7):2054–2063.
6. Carreño-Tarragona G, Cedena T, Montejano L, Alonso R, Miras F, Valeri A, et al. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies. Transfus Med. 2019;29(3):193–196.
7. Vũ Đức Bình, Bùi Thị Mai An, Hoàng Thị Thanh Nga. Nghiên cứu đặc điểm kháng thể bất thường hệ hồng cầu ở bệnh nhân bệnh máu tại Viện Huyết học – Truyền máu Trung ương năm 2011–2017. Tạp chí Y học Việt Nam. 2018;467:209–216.